Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs

Abstract

Apolipoprotein A-I (apo A-I), the major protein component of serum high density lipoproteins, was found to inhibit herpes simplex virus (HSV)-induced cell fusion at physiological (∼ 1 μ M) concentrations. An 18 amino acid-long synthetic amphipathic α-helical peptide analog of apo A-I (18A) was also found to inhibit HSV-induced cell fusion at similar concentration (∼ 2 μ M). Dimers of 18A connected via a proline (37pA) or an alanine (37aA) residue also inhibited virus-induced cell fusion at similar concentration, suggesting that the presence of a proline turn does not influence the antiviral activity of the amphipathic peptides. However, a peptide analog 18R, in which the distribution of charged residues was reversed, inhibited virus-induced cell fusion only at a higher (∼ 125 μ M) concentration, suggesting that the anti-viral activity of the amphipathic peptide is strongly influenced by the nature of the charge distribution at the polar-nonpolar interface. Consistent with their ability to inhibit virus-induced cell fusion, the peptides inhibited the spread of HSV infection as demonstrated by a 10-fold reduction in the virus yield, when virus-infected cells were maintained in the presence of amphipathic peptides. The amphipathic peptides also inhibited penetration of virus into cells, but did not exert any effect on virus adsorption. A nearly complete inhibition of virus penetration was observed when the virus, or both virus and cells, was pretreated with the peptide, suggesting that the peptides may have a direct effect on the virus. The results indicate that amphipathic helices may be useful in designing novel antiviral agents that inhibit penetration and spread of enveloped viruses.